Dual first-line maintenance by PARP inhibitor and bevacizumab can cause confusion in high-grade serous ovarian cancer: A case of PRES and a review of the literature

Aikaterini Liapi; Chirine Atat; Vincent Dunet; Apostolos Sarivalasis

doi:10.1177/2050313X231176401

Dual first-line maintenance by PARP inhibitor and bevacizumab can cause confusion in high-grade serous ovarian cancer: A case of PRES and a review of the literature

SAGE Open Med Case Rep. 2023 May 23:11:2050313X231176401. doi: 10.1177/2050313X231176401. eCollection 2023.

Authors

Aikaterini Liapi¹, Chirine Atat¹, Vincent Dunet¹, Apostolos Sarivalasis¹

Affiliation

¹ CHUV, Lausanne, Switzerland.

Abstract

Posterior reversible encephalopathy syndrome is a rare neurological disorder, the diagnosis of which is based on the combination of clinical and radiological findings. It can be associated with many patient-related conditions such as autoimmune disorders or can be provoked by toxins or medication. We report the case of a 70-year-old patient, known for International Federation of Gynecology and Obstetrics stage IVB, high-grade serous ovarian carcinoma, who was diagnosed with a posterior reversible encephalopathy syndrome while on bevacizumab and olaparib maintenance treatment.

Keywords: Posterior reversible encephalopathy syndrome (PRES); bevacizumab; olaparib; ovarian cancer.

Publication types

Case Reports